The American Association for Cancer Research has established the Cancer Evolution Working Group.
The mission of the AACR Cancer Evolution Working Group is to advance cancer diagnostic, therapeutic, and prevention strategies by fostering a fundamental understanding of cancer evolution amongst its members and the broader cancer research community. Membership in the AACR Cancer Evolution Working Group is free and open to all members of the AACR interested in cancer evolution.
The AACR Cancer Evolution Working Group will strive to accomplish its mission by working to:
- Facilitate transdisciplinary approaches to the study of cancer evolution and translate novel cancer evolution insights into new early detection, diagnostic, therapeutic, and preventive strategies to improve outcomes significantly and sustainably for cancer patients.
- Promote the incorporation of multiomic molecular (genetic, epigenetic, genomic, karyotype, transcriptomic, proteomic, epiproteomic, metabolic), cellular, and tissue-based concepts and techniques, as well as novel data science tools into well-designed cancer evolution studies of multiclonal cancer cells and of host immune system and tumor microenvironment co-development.
- Recommend scientific and educational programs to provide ongoing forum(s) for the scholarly discussion and development of effective approaches to the conduct and interpretation of cancer evolution studies, including an annual Cancer Evolution Special Conference, an ongoing monthly Cancer Evolution Seminar Series, and cancer evolution sessions at AACR Annual Meetings.
- Foster collaborations with individuals interested in this scientific area and with relevant AACR scientific working groups that are engaged in other scientific disciplines.
- Assist with the professional advancement of early- and mid-career investigators engaged in cancer evolution research.
- Establish a community of cancer evolution experts and other individuals interested in advancing progress in cancer evolution.
AACR Cancer Evolution Working Group Executive Committee members are:
- Frank H. Laukien, PhD (co-chair)
- Charles Swanton, MBPhD, FRCP, FMedSci, FRS, FAACR (co-chair)
- Anna D. Barker, PhD, FAACR (co-chair elect)
- Jeffrey P. Townsend, PhD (co-chair lect)
- Denis Noble, CBE, FRS, FMedSci, MAE
- Kenneth J. Pienta, MD
- George H. Poste, DVM, PhD, FRCPath, FMedSci, CBE, FRS
- Susan M. Rosenberg, PhD
- Jason A. Somarelli, PhD
- AACR Cancer Evolution Working Group Steering Committee members are:
- M. William Audeh, MD, MS
- Alberto Bardelli, PhD
- Michael C. Campbell, PhD
- Peter J. Campbell, MBChB, PhD
- Christina Curtis, PhD
- James V. DeGregori, PhD
- Robert A. Gatenby, MD
- Marco Gerlinger, MD
- Michael A. Gillette, MD, PhD
- Robert J. Gillies, PhD
- Trevor Graham, PhD
- Henry H. Q. Heng, PhD
- Giulia C. Kennedy, PhD
- Carlo C. Maley, PhD
- Perry S. Marshall, BS
- Andriy Marusyk, PhD
- Nicholas McGranahan, PhD
- Franziska Michor, PhD
- Paul S. Mischel, MD
- Nicholas E. Navin, PhD
- Serena Nik-Zainal, MBBCh, PhD
- Larry Norton, MD, FAACR
- Elizabeth O’Day, MPhil, PhD
- Azra Raza, MD
- Chan Soon-Shiong Professor of Medicine; Director, Myelodysplastic Syndrome Center, Columbia University, New York, NY
- Andrea Sottoriva, PhD
- Danny R. Welch, PhD
- Jonathan Weissman, PhD
A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.